TATX 22
Alternative Names: TATX-22Latest Information Update: 19 Oct 2022
At a glance
- Originator Talem Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Acute myeloid leukaemia; Solid tumours